Effect of restrictive intravenous fluid on the complications and quality of life in the advanced hepatocellular carcinoma patients

Abstract

Objective To investigate the effect of restrictive intravenous fluid on the complications and quality of life in the advanced hepatocellular carcinoma patients. Methods Clinical data of Three hundred and fifty-seven cases with advanced hepatocellular carcinoma from Mar 2010 to Mar 2016 was retrospectively analyzed. One hundred and sixty-eight cases were recruited in the restrictive intravenous fluid (RIF) group, and One hundred and eighty-nine cases were involved in the control group. The average volume of intravenous fluid of each day, plasma albumin concentration, splanchnocoel hydrops rate, phlebitis, incidence of vomiting, cancer related pain degree, anxiety degree were compared in the two groups. Results The average volume of intravenous fluid of each day in the RIF group [(720.29±106.84)ml] were much lower than that in the control group [(1 820.36±342.12)ml] (P<0.05). The plasma albumin concentration in the RIF group [(35.65±2.21)g/L] were higher than that in the control group [(32.25±2.32)g/L] (P<0.05). The rate of splanchnocoel hydrops, phlebitis, vomiting, bedsores, and hypostatic pneumonia in RIF group were 6.25%, 4.69%, 8.59%, 3.9%, 11.72% and those in the control group were 13.97%, 10.92%, 17.47%, 10.04%, and 24.45%, respectively (P<0.05). Moreover, the scores of cancer related pain and anxiety were much lower in the RIF group (5.21±1.09, 39.12±5.54) than those in the control group(5.68±1.18, 41.56±6.78) (P<0.01). Conclusions Restrictive intravenous fluid therapy can decrease the cancer associated complications and improved the quality of life in the advanced hepatocellular carcinoma patients. Key words: Fluid therapy; Liver neoplasms/CO/PC; Quality of life